Camber Capital Management Has Increased Gilead Sciences (Call) (GILD) Holding; Muzinich & Company Has Trimmed Its Ares Capital (ARCC) Stake

December 6, 2017 - By Henry Gaston

Camber Capital Management Llc increased Gilead Sciences Inc. (Call) (GILD) stake by 100% reported in 2017Q2 SEC filing. Camber Capital Management Llc acquired 1.00 million shares as Gilead Sciences Inc. (Call) (GILD)’s stock declined 8.05%. The Camber Capital Management Llc holds 2.00 million shares with $141.56M value, up from 1.00M last quarter. Gilead Sciences Inc. (Call) now has $95.74B valuation. It closed at $73.29 lastly. It is down 21.80% since December 6, 2016 and is downtrending. It has underperformed by 38.50% the S&P500.

Muzinich & Company decreased Ares Capital Corp (ARCC) stake by 6.62% reported in 2017Q2 SEC filing. Muzinich & Company sold 896,521 shares as Ares Capital Corp (ARCC)’s stock declined 6.68%. The Muzinich & Company holds 12.65M shares with $207.25 million value, down from 13.55M last quarter. Ares Capital Corp now has $6.92 billion valuation. The stock increased 0.87% or $0.14 during the last trading session, reaching $16.24. About 1.68M shares traded. Ares Capital Corporation (NASDAQ:ARCC) has risen 9.72% since December 6, 2016 and is uptrending. It has underperformed by 6.98% the S&P500.

Among 16 analysts covering Ares Capital (NASDAQ:ARCC), 11 have Buy rating, 0 Sell and 5 Hold. Therefore 69% are positive. Ares Capital had 25 analyst reports since August 21, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, September 20 by Oppenheimer. The stock has “Neutral” rating by National Securities on Tuesday, June 28. The stock of Ares Capital Corporation (NASDAQ:ARCC) earned “Buy” rating by Keefe Bruyette & Woods on Sunday, July 23. The firm has “Hold” rating given on Friday, October 6 by BMO Capital Markets. Barclays Capital maintained the stock with “Overweight” rating in Thursday, February 25 report. The rating was maintained by BMO Capital Markets with “Hold” on Wednesday, May 31. Jefferies maintained it with “Buy” rating and $19.5 target in Thursday, November 2 report. The stock of Ares Capital Corporation (NASDAQ:ARCC) has “Buy” rating given on Thursday, August 18 by UBS. The firm has “Buy” rating given on Wednesday, June 14 by Keefe Bruyette & Woods. Citigroup maintained it with “Buy” rating and $18 target in Friday, August 21 report.

Muzinich & Company increased Fs Investment Corp (NYSE:FSIC) stake by 193,652 shares to 9.67M valued at $88.48 million in 2017Q2. It also upped Alcentra Capital Corp (NASDAQ:ABDC) stake by 157,251 shares and now owns 610,164 shares. Tcp Capital Corp (NASDAQ:TCPC) was raised too.

Analysts await Ares Capital Corporation (NASDAQ:ARCC) to report earnings on February, 28. They expect $0.37 EPS, down 11.90% or $0.05 from last year’s $0.42 per share. ARCC’s profit will be $157.73M for 10.97 P/E if the $0.37 EPS becomes a reality. After $0.36 actual EPS reported by Ares Capital Corporation for the previous quarter, Wall Street now forecasts 2.78% EPS growth.

Investors sentiment decreased to 1.13 in Q2 2017. Its down 0.38, from 1.51 in 2017Q1. It worsened, as 63 investors sold ARCC shares while 88 reduced holdings. 43 funds opened positions while 127 raised stakes. 170.64 million shares or 4.44% less from 178.56 million shares in 2017Q1 were reported. Moors & Cabot Inc reported 20,884 shares. Webster Bancorp N A invested in 1,374 shares. West Oak Capital Lc holds 0% of its portfolio in Ares Capital Corporation (NASDAQ:ARCC) for 5,910 shares. Omers Administration invested 0.36% in Ares Capital Corporation (NASDAQ:ARCC). Dnb Asset Mgmt As stated it has 0% of its portfolio in Ares Capital Corporation (NASDAQ:ARCC). Raymond James Financial Serv Advisors Incorporated has 0.02% invested in Ares Capital Corporation (NASDAQ:ARCC) for 152,665 shares. Wealthcare Lc accumulated 179 shares. Paragon Capital Mgmt Limited holds 0.11% in Ares Capital Corporation (NASDAQ:ARCC) or 14,644 shares. Tru Company Of Vermont reported 0% in Ares Capital Corporation (NASDAQ:ARCC). Pioneer Investment accumulated 223,604 shares. Commonwealth Equity Services holds 309,135 shares or 0.03% of its portfolio. Segall Bryant And Hamill Llc invested in 619,400 shares or 0.24% of the stock. Advisory Services Ltd holds 23,011 shares or 0.05% of its portfolio. West Family Invests Inc reported 88,724 shares. Credit Suisse Ag reported 0% stake.

Camber Capital Management Llc decreased Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stake by 300,000 shares to 350,000 valued at $45.11 million in 2017Q2. It also reduced Endo Intl Plc (NASDAQ:ENDP) stake by 1.48 million shares and now owns 3.57M shares. Sarepta Therapeutics Inc (NASDAQ:SRPT) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: